EMEA-001741-PIP01-14-M05
Key facts
| Invented name |
Rinvoq
|
| Active substance |
upadacitinib
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0510/2021
|
| PIP number |
EMEA-001741-PIP01-14-M05
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
AbbVie Ltd
Tel.: +44 1628408248 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|